Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden

被引：0
|
作者：
Jonsson, L.
Ekman, M.
Karlsson, G.
Brun, J.
机构：
[1] European Hlth Econ, London, England
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] AstraZeneca, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63646-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A346 / A346
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
    Lindgren, P.
    Hagstrom, E.
    Van Hout, B.
    Villa, G.
    Urbich, M.
    Sandelin, R.
    Svensson, M. Eriksson
    Fonarow, G. C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 681 - 681
  • [2] Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice
    Ohsfeldt, Robert L.
    Gandhi, Sanjay K.
    Fox, Kathleen M.
    Stacy, Thomas A.
    McKenney, James M.
    AMERICAN JOURNAL OF MANAGED CARE, 2006, 12 (15): : S412 - S423
  • [3] Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review
    Zhou, Xilin
    Siegel, Karen R.
    Ng, Boon Peng
    Jawanda, Shawn
    Proia, Krista K.
    Zhang, Xuanping
    Albright, Ann L.
    Zhang, Ping
    DIABETES CARE, 2020, 43 (07) : 1593 - 1616
  • [4] Cost-effectiveness of ramipril in preventing cardiovascular events in high-risk patients
    Ganguly, R
    Parasuraman, TV
    VALUE IN HEALTH, 2003, 6 (03) : 321 - 322
  • [5] COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN VERSUS GENERIC ATORVASTATIN IN PATIENTS AT HIGH CARDIOVASCULAR RISK IN SPAIN
    Brosa, M.
    Barrios, V
    Lobos, J. M.
    Serrano, A.
    Capel, M.
    Alvarez, C.
    VALUE IN HEALTH, 2011, 14 (07) : A380 - A380
  • [6] Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States
    Hutchinson, Angela B.
    Farnham, Paul G.
    Sansom, Stephanie L.
    Yaylali, Emine
    Mermin, Jonathan H.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (03) : 323 - 330
  • [7] Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
    Peters, Mary Linton B.
    Eckel, Andrew
    Seguin, Claudia L.
    Davidi, Barak
    Howard, David H.
    Knudsen, Amy B.
    Pandharipande, Pari V.
    JCO ONCOLOGY PRACTICE, 2024, 20 (02) : 278 - 290
  • [8] COST-EFFECTIVENESS STUDIES - CAN BENEFIT BE SHOWN ONLY IN HIGH-RISK POPULATIONS
    YUSUF, S
    BOSCH, J
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1995, : 22 - 25
  • [9] Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain
    Cosin Sales, Juan
    Fuentes Jimenez, Francisco Jose
    Mantilla Morato, Teresa
    Ruiz, Emilio
    Becerra, Virginia
    Aceituno, Susana
    Giovanna Ferrario, Maria
    Lizan, Luis
    Gracia, Alfredo
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2015, 27 (05): : 228 - 238
  • [10] COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK
    Garcia-Goni, M.
    Facila, L.
    Cinza, S.
    Pinto, X.
    Cortes, X.
    Prades, M.
    Aceituno, S.
    VALUE IN HEALTH, 2018, 21 : S104 - S105
12345